60 Degrees Pharmaceuticals (SXTP) Projected to Post Quarterly Earnings on Wednesday

60 Degrees Pharmaceuticals (NASDAQ:SXTP) will likely be issuing its Q1 2025 quarterly earnings data before the market opens on Wednesday, May 21st. Analysts expect the company to announce earnings of ($1.31) per share for the quarter.

60 Degrees Pharmaceuticals Price Performance

SXTP stock opened at $2.39 on Wednesday. 60 Degrees Pharmaceuticals has a 1 year low of $1.41 and a 1 year high of $35.99. The company has a market cap of $3.52 million, a P/E ratio of -0.24 and a beta of 3.02. The stock’s fifty day moving average price is $2.35 and its 200-day moving average price is $3.87.

Analyst Ratings Changes

Several research analysts have issued reports on the company. HC Wainwright reissued a “neutral” rating on shares of 60 Degrees Pharmaceuticals in a research report on Friday, March 28th. Weiss Ratings reissued a “sell (e+)” rating on shares of 60 Degrees Pharmaceuticals in a report on Saturday.

60 Degrees Pharmaceuticals Company Profile

60 Degrees Pharmaceuticals, Inc, a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal pneumonias, and candidiasis disease; and Celgosivir for respiratory viruses and dengue.